Minn. legislators to FDA: Don’t tread on device makers

MedCity News logo

A pair of Minnesota legislators are lobbying against changes the Food & Drug Administration proposes for its 510(k) clearance protocol the industry says will hurt innovation and the state’s economy.

U.S. Sen. Amy Klobuchar (D:Minn.) and Rep. Erik Paulsen (R:Minn.) sent a letter to FDA Commissioner Dr. Margaret Hamburg, warning that overzealous regulation would hurt start-ups struggling to raise venture capital in a weak economy.

Sen. Amy Klobuchar (D:Minn.)


Rep. Erik Paulsen (R:Minn.)


“Bringing a new medical device to market typically involves millions, sometimes hundreds of millions, of dollars in upfront research and development costs,” wrote Klobuchar, chair of the Senate Commerce Subcommittee on Competitiveness, Innovation and Export Promotion, and Paulsen, chair of the Medical Technology Caucus. “The suggested changes could threaten the availability of often relied on equity investments.”

Calls to both Klobuchar’s and Paulsen’s offices seeking an explanation of the specific changes to the 510(k) program that concern the legislators were not immediately returned.

The letter comes about a week after Dr. Jeffrey Shuren, director of the agency’s Center for Devices and Radiological Health, met with local industry officials in a town hall forum in Bloomington, Minn.

Here’s the full text of the letter:

May 25, 2010

Dr. Margaret Hamburg
Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20993-0002

Dear Dr. Hamburg,

Thank you for your service in your role as Commissioner of the Food and Drug Administration (FDA). We are writing to express concerns regarding the FDA’s proposed changes to the 510 (k) approval process for medical devices.

This is an issue of particular importance to our home state of Minnesota. Our state has led medical innovation for more than 60 years and boasts more than 400 medical device companies that together employ over 50,000 people. In the last few weeks, we’ve had the opportunity to speak with a number of medical device companies, many of which attended the FDA’s town hall meeting on May 18, 2010 in Bloomington, Minnesota regarding recent changes in the FDA’s approval process.

We support your agency’s goal to improve the FDA’s policies and procedures to ensure only safe and effective devices reach the marketplace. We also applaud your willingness to meet personally with our state’s medical device industry to discuss how they can have the most productive collaboration. This is essential for American patients to continue to have access to the best, most advanced medical technology possible.

However, we are concerned that some policy changes under consideration by the FDA would add new and unnecessary regulations, resulting in an even longer and more complicated approval process.

In addition to creating an undue regulatory burden, these changes would increase the time, cost and risk associated with developing new medical technology.

Bringing a new medical device to market typically involves millions, sometimes hundreds of millions, of dollars in upfront research and development costs. The suggested changes could threaten the availability of often relied on equity investments. Already, FDA’s increasingly slow and inconsistent approval system has dampened investment in small medical device firms. In the last two years, venture capital funding alone dropped by one-third. Efforts to further restrict the approval process would only compound those declines, jeopardizing 83% of jobs in the medical technology sector and threatening our nation’s $5.4 billion trade surplus in medical device exports.

For decades, the FDA and the medical device industry enjoyed a successful partnership– one that allowed them to ensure new products were appropriately vetted, and innovative technologies were adequately supported. We urge the FDA to maintain that tradition of cooperation today, and to reject proposals that unduly burden small businesses and suppress the development of promising medical breakthroughs.

Thank you for your consideration of this important issue.


Amy Klobuchar
United States Senator

Erik Paulsen
United States Representative

RSS From Medical Design & Outsourcing

  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]
  • Cosasco’s wireless communications protocol makes electrically hazardous areas safer
    Cosasco has expanded the functionality of its CWT-9020 wireless water system corrosion monitor for electrically hazardous areas by offering ISA100 Wireless communications protocol. Along with WirelessHART 7, the new protocol option allows the transmitter to integrate with an even wider range of existing wireless systems. ISA100 Wireless supports more wireless devices and provides an effective […]
  • Vicon captures a new development in motion capture (mocap)
    Vicon announced the launch of its new flagship camera platform, the Vicon Vantage. Drawing on over 30 years’ of motion capture (mocap) experience, the Vantage platform combines innovative technology with accessible design to open up motion capture to a broader audience. Vicon is a motion capture technology specialist company for science and life industries. Advances in […]
  • Satel’s latest product sets a new milestone in radio manufacturing
    The new Satelline TR4, from the Finnish manufacturer of radio data transmission systems, Satel sets a new milestone. The compact UHF transceiver with transmitting power of 1,000 mW is compatible with the protocols of Pacific Crest, Trimble and Satel. The type certifications in all important regions of the world make the TR4 ideal for integration […]
  • SCHURTER announces retirement of founder and management changes
    SCHURTER announced the retirement of founder Bruno H. Schurter on June 29, 2015. The company, founded in 1982 in Petaluma, California, will change management effective July 1, 2015. Bruno H. Schurter, president and CEO will retire after 33 years of heading up the privately held company, which is a subsidiary of SCHURTER Holding AG, founded in […]
  • Silicone: Expanding the horizon for modern medical devices
    Editor’s note: This article comes from Albright Technologies a manufacturer of custom silicone prototypes and provides volume production for medical, pharmaceutical, industrial, and other applications. Silicone materials have been around for more than 70 years. Beginning in the 1960s, silicones have played an important and evolving part in products designed for the medical field. Since that time, […]
  • DeNovo Sciences appoints a molecular diagnostics veteran as new CSO
    DeNovo Sciences, a producer of  liquid biopsy products, announced the appointment of Dr. Yixin Wang as Chief Scientific Officer (CSO). Dr. Wang is a veteran in molecular diagnostics where he has played significant R&D roles at large, multi-national companies including Parke-Davis/Pfizer, Veridex/Johnson & Johnson and Ventana/Roche. He will lead strategic initiatives for clinical development of DeNovo’s […]
  • Albright Technologies expands their silicone offerings
    Albright Technologies, a rapid silicone prototyper, has added silicone injection molding tooling and services to its product lineup. Liquid silicone injection molding became a suitable product offering as Albright expanded its offerings to better serve the silicone molding market. While silicone prototypes are commonly manufactured with low volumes in mind; injection molded liquid silicone rubber parts are […]
  • Applied Silver launches SilvaClean, silver treatment for textiles
    Applied Silver, Inc, is launching SilvaClean, a state-of-the-art silver treatment for textiles, at the Association for Professionals in Infection Control and Epidemiology’s (APIC) forty-second Annual Conference taking place at the Music City Center in Nashville, from June 27 through June 29. Hospitals have invested significantly in reducing the potential of infection through products and processes designed […]
  • Two-Component technology for improved quality of life
    In the field of injection molding and mold making, toolcraft covers all processes within the added value chain–from the design and selection of materials through to the creation of finished and qualified products. Complete solutions offered include injection molding for parts in the small and extremely small component areas, e.g. for medical technology. Utilizing two-component […]

Leave a Reply